for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

China Medical System Holdings

0867.HK

Latest Trade

12.40HKD

Change

0.18(+1.47%)

Volume

2,712,455

Today's Range

12.06

 - 

12.52

52 Week Range

6.14

 - 

13.08

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
12.22
Open
12.08
Volume
2,712,455
3M AVG Volume
165.58
Today's High
12.52
Today's Low
12.06
52 Week High
13.08
52 Week Low
6.14
Shares Out (MIL)
2,480.41
Market Cap (MIL)
30,310.59
Forward P/E
12.17
Dividend (Yield %)
3.09

Next Event

Full Year 2019 China Medical System Holdings Ltd Earnings Release

Latest Developments

More

Sun Pharmaceutical Industries Enters Licensing Agreement With China Medical System Holdings

China Medical System Holdings HY Turnover Up 11.7%

China Medical System Signs License Agreement With Unit Of Sun Pharmaceutical Industries

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About China Medical System Holdings

China Medical System Holdings Limited is a Hong Kong-based investment holding company principally engaged in the manufacture, marketing, promotion and sales of pharmaceutical products. Its main products under direct network include Deanxit, Ursofalk, XinHuoSu, Salofalk, Bioflor and Augentropfen Stulln Mono Eye-drops, among others. Its products under the agency promotion network include ShaDuoLiKa, YiNuoShu and XiDaKang, among others. The products of the Company are used in the treatment of gastropathy, cardiopathy, traumatic infection, hepatopathy and eye diseases, among others.

Industry

Biotechnology & Drugs

Contact Info

Suite 3308, Two Exchange Square, Central

+86.755.82416868

http://www.cms.net.cn/

Executive Leadership

Kong Lam

Executive Chairman of the Board, Chief Executive Officer, President

Yanling Chen

Chief Financial Officer, Vice President, Executive Director

Hongbing Chen

Chief Operating Officer, Vice President, Executive Director

Sanyan Wu

Company Secretary

Kam Shing Cheung

Independent Non-Executive Director

Key Stats

2.18 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

4.9K

2017

5.3K

2018

5.4K

2019(E)

6.1K
EPS (CNY)

2016

0.553

2017

0.673

2018

0.744

2019(E)

0.885
Price To Earnings (TTM)
13.17
Price To Sales (TTM)
4.73
Price To Book (MRQ)
2.96
Price To Cash Flow (TTM)
12.03
Total Debt To Equity (MRQ)
15.73
LT Debt To Equity (MRQ)
0.07
Return on Investment (TTM)
22.02
Return on Equity (TTM)
19.07

Latest News

Latest News

BRIEF-China Medical System Through Unit Signs License And Collaboration Agreement With VAXIMM AG

* GROUP THROUGH UNIT SIGNED LICENSE AND COLLABORATION AGREEMENT WITH VAXIMM AG

BRIEF-China Medical System Holdings Trading In Shares Halted

* TRADING IN SHARES HALTED AT 9:07 A.M. ON MAY 7 Source text for Eikon: Further company coverage:

BRIEF-China Medical System Posts FY Profit Attributable Of ‍RMB1.67 Bln

* FY PROFIT ATTRIBUTABLE RMB1,669.9 MILLION VERSUS RMB1,377.9 MILLION Source text for Eikon: Further company coverage:

BRIEF-China Medical System says ‍Sa Manlin resigned as executive director​

* Sa Manlin resigned as an executive director Source text for Eikon: Further company coverage:

BRIEF-China Medical System Holdings Ltd says unit enters into agreement with Destiny Pharma Plc

* Unit entered into a binding investment, development and commercialisation framework agreement with Destiny Pharma Plc Source text for Eikon: Further company coverage:

BRIEF-China Medical System Holdings says Sky United Trading enters facility agreement with Standard Chartered Bank (Hong Kong) as original lender and agent

* Sky United Trading Ltd and co enter facility agreement with standard chartered bank (hong kong) (original lender and agent)

BRIEF-China Medical System FY Profit up 38.3 pct

* Profit for year up 38.3 pct to RMB1,377.9 million Source text for Eikon: Further company coverage:

BRIEF-China Medical System Holdings updates on placing application by Tibet Pharmaceutical

* Tibet Pharmaceutical announced that placing application by Tibet Pharmaceutical has been approved by China Securities Regulatory Commission Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up